Independent review
MEDVi review: GLP‑1 pricing and terms
What we could verify
$199advertised
GLP-1 Injections
$99 for the first month
Billing term not stated, so we do not compare it
2 figures published, none with a billing term
✓ Figure read 5 Nov 2026
Cancellation
Through support
MEDVi's own site, not a paid placement
What MEDVi charges, read from its own pages on 5 Nov 2026.
What stands out
- Dose pricing Dose schedule not recorded
- Insurance Files no insurance claims
- Regulatory record FDA warning letter, Feb 2026
- Legal entity Legal entity published
- Cancellation Cancel by contacting support
MEDVi's lowest advertised GLP-1 figure is $199, after $99 for the first month, checked 5 Nov 2026. It does not state how long a plan runs.
MEDVi sells a compounded weekly injection and a compounded daily tablet. Neither price card names a molecule, though its FAQ calls the injection program semaglutide. It also carries an FDA warning letter, so read the record before a customer rating decides it for you.
Verdict: We would not send you to MEDVi first. FDA issued a warning letter to MEDVi, LLC in February 2026 over the labelling of its compounded products and the claims on its site. Its price cards name no molecule; only its FAQ calls the injection program semaglutide. Its branded cards add a membership fee to a medication price MEDVi does not publish. A high customer rating does not answer a regulator's letter.
- Names its legal entity in full, down to the state of incorporation and a street address, so there is a company to look up if a charge goes wrong.
- Sells a weekly injection and a daily tablet, so changing format does not mean changing provider.
- Our change log records each change to its membership terms, so the current terms are not the only terms you can see.
Quick facts
How much does MEDVi cost?
MEDVi's lowest advertised GLP-1 figure is $199, after $99 for the first month, checked 5 Nov 2026. It does not state how long a plan runs.
Price changes appear in the change log.
| Plan | Medication | Price | What's included |
|---|---|---|---|
| GLP-1 Injections, GLP-1 Injections, Starting at, one injection per week | Molecule not named Compounded | $199 advertised $99 for the first month Billing term not stated, so this is not comparable Figure read | Not stated by the provider |
| GLP-1 oral (molecule not named), GLP-1 Tablets, Starting at, one dissolvable tablet per day | Molecule not named Compounded | $249 advertised Billing term not stated, so this is not comparable Figure read | Same as above |
HSA/FSA accepted where the provider states it; insurance is not billed directly. None of these plans currently carries a dated price, so every figure reads "Not published" rather than an estimate.
Where it falls short
Two things, and the second is the one most readers will hit first. MEDVi prices each product as a starting figure and publishes no dose schedule, and it names no molecule on either product, so the price does not tell you what you are buying or what the next dose up costs. The membership fee MEDVi advertises is on its branded cards, whose medication price it does not publish, so the branded route has no monthly total we can give you. The other is the record: FDA addressed a letter to MEDVi, LLC in February 2026, and what it addressed was the company's own labelling and the claims on its site rather than a complaint about an order.
- FDA issued a warning letter to MEDVi, LLC in February 2026 over its product labelling and its site claims. Cited to the FDA's own record on this page.
- Its price cards name no molecule, so the figure does not tell you what you would be taking. Only its FAQ calls the injection program semaglutide.
- Prices each product as a starting figure with no dose schedule behind it, so a higher dose has no knowable cost.
- Its membership fee applies to its branded cards, and their medication price is not published, so the branded route has no monthly total we can give you.
How MEDVi compares
More columns to the right. Drag or swipe the table.
| Metric |
|
|
|
|
|---|---|---|---|---|
| VerifiedDose score | Not scored | 7.9 | 7.9 | 8.7 |
| From | Not published No plan on file | $149 Price verified ✓ Price checked | $1,399 Price verified ✓ Price checked | $65 12-month plan, $780 at this rate Price verified ✓ Price checked |
| Insurance | Files no insurance claims | Files claims | Not recorded | Files claims |
How it works
MEDVi terms: what the provider states about its model, timing, insurance and cancellation.
- Model
- Compounded
- Membership fee
- Not published
- Insurance
- Files no claims on your behalf
- Time to prescription
- Not stated
- Cancellation
- Message or call support
- States served
- Not recorded
- Refunds
- Full refund if you notify patient support within 72 hours and have received no services, or on medical disqualification; on a monthly plan, no refund for the month you cancel or earlier onesRead 27 Oct 2026 on home.medvi.org (opens in a new tab)
- VerifiedDose score
- Not scored: no dated price to weight. How we rate providers.
MEDVi reviews
Is MEDVi legit? Its company and regulatory record
We don't certify companies; this is the record we hold for MEDVi. Legal entity on file: MEDVi, LLC, a Delaware corporation, 131 Continental Dr Ste 305, Newark DE 19713. We hold 1 record on file for it, each with its source below; the latest is an FDA warning letter dated 20 Feb 2026.
We check its prices by hand; the latest reading is from 5 Nov 2026. Third-party reputation: Trustpilot 4.3 from 15,046 reviews, read 19 Oct 2026. Official domain: https://home.medvi.org/.
Regulatory record
-
FDA warning letter
FDA warned MEDVi that its compounded semaglutide and tirzepatide were misbranded: the pictured labels carried MEDVi's own name, suggesting it was the compounder when it was not, and site claims — "Same active ingredient as Wegovy and Ozempic" — implied FDA approval the products do not have.
FDA warning letter 721455, primary source (opens in a new tab)
What has changed
-
Price decreased
MEDVi $299 → $199
Observation and source
Seen on the provider's own page on 26 Oct 2026, recorded here on 26 Oct 2026.
GLP-1 Injections, Starting at, one injection per week GLP-1 Injections, Starting at, one injection per week — read from the provider's own page on 26 Oct 2026.
The page this was read from (opens in a new tab) -
Our record corrected
MEDVi $149 → $299
Observation and source
Seen on the provider's own page on 13 Oct 2026, recorded here on 13 Oct 2026.
Correction to our record, not a change at MEDVi.
The page this was read from (opens in a new tab) -
Required fee withdrawn
MEDVi $99 → not published
Observation and source
Recorded here on 8 Oct 2026. This entry predates our observation log, so the day the provider's page changed is not on file.
-
Insurance filing changed
MEDVi not established → files no claims
Observation and source
Recorded here on 6 Oct 2026. This entry predates our observation log, so the day the provider's page changed is not on file.
-
Plan label corrected
MEDVi Semaglutide/Tirzepatide (GLP-1, molecule not named) → GLP-1 Injections
Observation and source
Recorded here on 24 Aug 2026. This entry predates our observation log, so the day the provider's page changed is not on file.
Correction to our label, not a change at the provider.
The page this was read from (opens in a new tab) -
First required fee on record
MEDVi not published → $99
Observation and source
Recorded here on 13 Aug 2026. This entry predates our observation log, so the day the provider's page changed is not on file.
Read from the provider's own page.
The page this was read from (opens in a new tab) -
Provider status changed
MEDVi Shut down → Active
Observation and source
Recorded here on 13 Aug 2026. This entry predates our observation log, so the day the provider's page changed is not on file.
Recorded as shut down on a stale domain. The brand is trading at the URL above.
The page this was read from (opens in a new tab) -
Price published again
MEDVi not published → $249
Observation and source
Seen on the provider's own page on 12 Aug 2026, recorded here on 20 Aug 2026.
GLP-1 (molecule not published) — verified 12 Aug 2026
The page this was read from (opens in a new tab) -
First price on record
MEDVi not published → $149
Observation and source
Seen on the provider's own page on 12 Aug 2026, recorded here on 20 Aug 2026.
GLP-1 (molecule not published) — verified 12 Aug 2026
The page this was read from (opens in a new tab) -
Provider status changed
MEDVi Active → Shut down
Observation and source
Recorded here on 9 Aug 2026. This entry predates our observation log, so the day the provider's page changed is not on file.
Checked 09 Aug 2026: medvi.com and medvi.io both fail to serve: Cloudflare returns 522, meaning the origin server accepted the connection and never answered.
The page this was read from (opens in a new tab)
The record, and what a rating does not settle
FDA's letter says what it was about, so this page says the same and stops there. The agency wrote about labels pictured on MEDVi's own site and about the wording on the pages around them. That is a regulator acting on a company's published material. It is not a court judgment and it is not a recall. The claim below is FDA's wording rather than ours, and the link goes to the agency's record so you can read it yourself. The customer rating further down this page comes from buyers describing their own orders, which answers a different question.
FDA issued a warning letter to MEDVi, LLC dba MEDVi stating that its compounded semaglutide and tirzepatide were misbranded, that labels pictured on its site carried MEDVi's own name although MEDVi was not the compounder, and that claims on the site implied an FDA approval the products do not have.
FDA 20 Feb 2026 Primary source (opens in a new tab)Two products, and the price cards name no molecule
MEDVi lists a weekly injection and a daily dissolvable tablet. Both are compounded preparations rather than the branded drug. Neither price card says which molecule it contains. Its FAQ calls the injection program a semaglutide program, and nothing we read names the tablet's molecule. We left the molecule blank on both rows, because a price belongs to the product on its own card. A molecule we filled in would look exactly like one the company named, and only one of those is true.
Each figure is a starting price rather than a rate for a dose, and MEDVi publishes no schedule behind it. Read the table above as the floor and not the ceiling. The membership fee is a separate question. MEDVi's branded cards add one to a medication price it does not publish, while its compounded products are priced with no membership line, so we hold no membership figure against the plans in the table.
Questions readers ask
Is MEDVi legitimate?
It is a named, trading company, MEDVi, LLC, incorporated in Delaware. It also carries an FDA warning letter, dated and sourced above. We publish both and we do not settle the question for you.
What is in MEDVi's products?
The price cards do not say. They read "GLP-1 Injections" and "GLP-1 Tablets". MEDVi's FAQ calls the injection program a semaglutide program, and nothing we read names the tablet. We left the molecule blank on both rows rather than attach one from an FAQ sentence.
Does MEDVi charge a membership fee?
On its branded cards, yes. When we read them in August, each carried a membership line on top of a medication cost MEDVi does not publish. Its compounded injection and tablet are priced without a membership line, so this page shows no membership figure beside them.
Its customer rating is high. Why does the review still read this way?
The two measure different things. A rating is a tally of how orders went for the people who left one. The entry above is a regulator's action, with the agency's own record linked. We publish both and let neither answer the other.
Does MEDVi take insurance?
We could not establish it. The field is blank because we did not confirm it either way, not because the answer is no.
Where it prescribes
No state coverage on file for MEDVi.
Sources
- MEDVi's own website and terms of service, read 5 Nov 2026
- FDA warning letter 721455 (FDA warning letter, 20 Feb 2026): https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medvi-llc-dba-medvi-721455-02202026 (opens in a new tab)